These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
288 related articles for article (PubMed ID: 28118606)
1. Protein S drives oral squamous cell carcinoma tumorigenicity through regulation of AXL. Abboud-Jarrous G; Priya S; Maimon A; Fischman S; Cohen-Elisha M; Czerninski R; Burstyn-Cohen T Oncotarget; 2017 Feb; 8(8):13986-14002. PubMed ID: 28118606 [TBL] [Abstract][Full Text] [Related]
2. Galectin-3 Stimulates Tyro3 Receptor Tyrosine Kinase and Erk Signalling, Cell Survival and Migration in Human Cancer Cells. Al Kafri N; Hafizi S Biomolecules; 2020 Jul; 10(7):. PubMed ID: 32664510 [TBL] [Abstract][Full Text] [Related]
3. AXL, along with PROS1, is overexpressed in papillary thyroid carcinoma and regulates its biological behaviour. Wei M; Wang Y; Liu Y; Li D; He X World J Surg Oncol; 2022 Oct; 20(1):334. PubMed ID: 36203174 [TBL] [Abstract][Full Text] [Related]
4. TAM family receptors in conjunction with MAPK signalling are involved in acquired resistance to PI3Kα inhibition in head and neck squamous cell carcinoma. Ruicci KM; Meens J; Plantinga P; Stecho W; Pinto N; Yoo J; Fung K; MacNeil D; Mymryk JS; Barrett JW; Howlett CJ; Boutros PC; Ailles L; Nichols AC J Exp Clin Cancer Res; 2020 Oct; 39(1):217. PubMed ID: 33059733 [TBL] [Abstract][Full Text] [Related]
5. Tumor-associated macrophages promote oral cancer progression through activation of the Axl signaling pathway. Lee CH; Liu SY; Chou KC; Yeh CT; Shiah SG; Huang RY; Cheng JC; Yen CY; Shieh YS Ann Surg Oncol; 2014 Mar; 21(3):1031-7. PubMed ID: 24276640 [TBL] [Abstract][Full Text] [Related]
6. Receptor tyrosine kinases, TYRO3, AXL, and MER, demonstrate distinct patterns and complex regulation of ligand-induced activation. Tsou WI; Nguyen KQ; Calarese DA; Garforth SJ; Antes AL; Smirnov SV; Almo SC; Birge RB; Kotenko SV J Biol Chem; 2014 Sep; 289(37):25750-63. PubMed ID: 25074926 [TBL] [Abstract][Full Text] [Related]
7. Cancer-associated fibroblasts contribute to oral cancer cells proliferation and metastasis via exosome-mediated paracrine miR-34a-5p. Li YY; Tao YW; Gao S; Li P; Zheng JM; Zhang SE; Liang J; Zhang Y EBioMedicine; 2018 Oct; 36():209-220. PubMed ID: 30243489 [TBL] [Abstract][Full Text] [Related]
8. Inactivation of GSK3β and activation of NF-κB pathway via Axl represents an important mediator of tumorigenesis in esophageal squamous cell carcinoma. Paccez JD; Duncan K; Vava A; Correa RG; Libermann TA; Parker MI; Zerbini LF Mol Biol Cell; 2015 Mar; 26(5):821-31. PubMed ID: 25568334 [TBL] [Abstract][Full Text] [Related]
9. Repression of AXL expression by AP-1/JNK blockage overcomes resistance to PI3Ka therapy. Badarni M; Prasad M; Balaban N; Zorea J; Yegodayev KM; Joshua BZ; Dinur AB; Grénman R; Rotblat B; Cohen L; Elkabets M JCI Insight; 2019 Mar; 5(8):. PubMed ID: 30860495 [TBL] [Abstract][Full Text] [Related]
10. The receptor tyrosine kinase AXL promotes migration and invasion in colorectal cancer. Uribe DJ; Mandell EK; Watson A; Martinez JD; Leighton JA; Ghosh S; Rothlin CV PLoS One; 2017; 12(7):e0179979. PubMed ID: 28727830 [TBL] [Abstract][Full Text] [Related]
11. AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma. Brand TM; Iida M; Stein AP; Corrigan KL; Braverman CM; Coan JP; Pearson HE; Bahrar H; Fowler TL; Bednarz BP; Saha S; Yang D; Gill PS; Lingen MW; Saloura V; Villaflor VM; Salgia R; Kimple RJ; Wheeler DL Clin Cancer Res; 2015 Jun; 21(11):2601-12. PubMed ID: 25767293 [TBL] [Abstract][Full Text] [Related]
12. Activation of the Receptor Tyrosine Kinase AXL Regulates the Immune Microenvironment in Glioblastoma. Sadahiro H; Kang KD; Gibson JT; Minata M; Yu H; Shi J; Chhipa R; Chen Z; Lu S; Simoni Y; Furuta T; Sabit H; Zhang S; Bastola S; Yamaguchi S; Alsheikh H; Komarova S; Wang J; Kim SH; Hambardzumyan D; Lu X; Newell EW; DasGupta B; Nakada M; Lee LJ; Nabors B; Norian LA; Nakano I Cancer Res; 2018 Jun; 78(11):3002-3013. PubMed ID: 29531161 [TBL] [Abstract][Full Text] [Related]
13. Axl is a prognostic marker in oral squamous cell carcinoma. Lee CH; Yen CY; Liu SY; Chen CK; Chiang CF; Shiah SG; Chen PH; Shieh YS Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S500-8. PubMed ID: 21842265 [TBL] [Abstract][Full Text] [Related]
14. AXL receptor kinase is a mediator of YAP-dependent oncogenic functions in hepatocellular carcinoma. Xu MZ; Chan SW; Liu AM; Wong KF; Fan ST; Chen J; Poon RT; Zender L; Lowe SW; Hong W; Luk JM Oncogene; 2011 Mar; 30(10):1229-40. PubMed ID: 21076472 [TBL] [Abstract][Full Text] [Related]
15. AXL mediates resistance to cetuximab therapy. Brand TM; Iida M; Stein AP; Corrigan KL; Braverman CM; Luthar N; Toulany M; Gill PS; Salgia R; Kimple RJ; Wheeler DL Cancer Res; 2014 Sep; 74(18):5152-64. PubMed ID: 25136066 [TBL] [Abstract][Full Text] [Related]
16. N-myc downstream-regulated gene 1 downregulates cell proliferation, invasiveness, and tumorigenesis in human oral squamous cell carcinoma. Lee JC; Chung LC; Chen YJ; Feng TH; Juang HH Cancer Lett; 2014 Dec; 355(2):242-52. PubMed ID: 25218595 [TBL] [Abstract][Full Text] [Related]
17. Silencing of PROS1 induces apoptosis and inhibits migration and invasion of glioblastoma multiforme cells. Che Mat MF; Abdul Murad NA; Ibrahim K; Mohd Mokhtar N; Wan Ngah WZ; Harun R; Jamal R Int J Oncol; 2016 Dec; 49(6):2359-2366. PubMed ID: 27840905 [TBL] [Abstract][Full Text] [Related]
18. Role of tumour-associated macrophages in oral squamous cells carcinoma progression: an update on current knowledge. Petruzzi MN; Cherubini K; Salum FG; de Figueiredo MA Diagn Pathol; 2017 Apr; 12(1):32. PubMed ID: 28381274 [TBL] [Abstract][Full Text] [Related]
19. The crosstalk between AXL and YAP promotes tumor progression through STAT3 activation in head and neck squamous cell carcinoma. Li J; Shi C; Zhou R; Han Y; Xu S; Ma H; Zhang Z Cancer Sci; 2020 Sep; 111(9):3222-3235. PubMed ID: 32589311 [TBL] [Abstract][Full Text] [Related]
20. Axl and Mertk Receptors Cooperate to Promote Breast Cancer Progression by Combined Oncogenic Signaling and Evasion of Host Antitumor Immunity. Davra V; Kumar S; Geng K; Calianese D; Mehta D; Gadiyar V; Kasikara C; Lahey KC; Chang YJ; Wichroski M; Gao C; De Lorenzo MS; Kotenko SV; Bergsbaken T; Mishra PK; Gause WC; Quigley M; Spires TE; Birge RB Cancer Res; 2021 Feb; 81(3):698-712. PubMed ID: 33239426 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]